anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rationale: Adult and pediatric studies provide conflicting data regarding whether post-cardiac arrest hypoxemia, hyperoxemia, hypercapnia, and/or hypocapnia are associated with worse outcomes. Objectives: We sought to determine whether postarrest hypoxemia or postarrest hyperoxemia is associated with lower rates of survival to hospital discharge, compared with postarrest normoxemia, and whether postarrest hypocapnia or hypercapnia is associated with lower rates of survival, compared with postarrest normocapnia. Methods: An embedded prospective observational study during a multicenter interventional cardiopulmonary resuscitation trial was conducted from 2016 to 2021. Patients ⩽18 years old and with a corrected gestational age of ≥37 weeks who received chest compressions for cardiac arrest in one of the 18 intensive care units were included. Exposures during the first 24 hours postarrest were hypoxemia, hyperoxemia, or normoxemia-defined as lowest arterial oxygen tension/pressure (PaO2) <60 mm Hg, highest PaO2 ⩾200 mm Hg, or every PaO2 60-199 mm Hg, respectively-and hypocapnia, hypercapnia, or normocapnia, defined as lowest arterial carbon dioxide tension/pressure (PaCO2) <30 mm Hg, highest PaCO2 ⩾50 mm Hg, or every PaCO2 30-49 mm Hg, respectively. Associations of oxygenation and carbon dioxide group with survival to hospital discharge were assessed using Poisson regression with robust error estimates. Results: The hypoxemia group was less likely to survive to hospital discharge, compared with the normoxemia group (adjusted relative risk [aRR] = 0.71; 95% confidence interval [CI] =  0.58-0.87), whereas survival in the hyperoxemia group did not differ from that in the normoxemia group (aRR = 1.0; 95% CI = 0.87-1.15). The hypercapnia group was less likely to survive to hospital discharge, compared with the normocapnia group (aRR = 0.74; 95% CI = 0.64-0.84), whereas survival in the hypocapnia group did not differ from that in the normocapnia group (aRR = 0.91; 95% CI = 0.74-1.12). Conclusions: Postarrest hypoxemia and hypercapnia were each associated with lower rates of survival to hospital discharge.
PURPOSE:To develop the study of cancers and tumors so as to quickly and easily diagnose them by using an antibody obtained by using the link of a antigenic peptide having a specific amino acid sequence and carrier protein as an antigen. CONSTITUTION:Antigenic peptide having a specific amino acid sequence and carrier protein are linked with each other by a well known method and an antibody is obtained by giving the link to an animal, such as mouse, etc., as an antigen with the purpose of causing immunity in the bodies of the animal. By using the obtained refined antibody and alkaline phosphastase-binding anti-rabbit IgG antibody, the product of a tumor-represser gene MCC is detected. As a result, the existence of a protein having a prescribed molecular weight is discovered from a semian fibroblast strain CV-1 expressing the tumor-represser gene MCC. Since such an antibody specifically recognizes the product of the tumor-represser gene, it can be utilized for analyzing the occurrence of cancers and tumors and diagnosing the cancers and tumors. In addition, since the antibody is manufactured by using an antigen composed only of the peptide which has a short chain and other substances prepared by using methods which are well known in the field of biological engineering, it can be manufactured easily.
OBJECTIVE: We aim to develop a predictive model for lymphovascular invasion (LVI) in patients with invasive breast cancer (IBC), using magnetic resonance imaging (MRI)-based radiomics features.
METHODS: A total of 204 patients with IBC admitted to our hospital were included in this retrospective study. The data was split into training and validation sets at a 7:3 ratio. Feature normalization was conducted, followed by feature selection using ANOVA, correlation analysis, and LASSO in the training set. The final step involved building a logistic regression model. The LVI prediction models were established by single sequence image and combined different sequence images as follows: A: prediction model based on the optimal sequence in the 7-phase enhanced MRI scans; B: prediction model based on the optimal sequences in the sequences T1WI, T2WI, and DWI; and C: the combined model based on the optimal sequences selected from A and B. Subjects' work characteristic curves (ROC) and decision curves (DCA) were plotted to determine the extent to which they predicted LVI performance in the training and validation sets. Simultaneously, nomogram models were constructed by integrating radiomics features and independent risk factors. In addition, an additional 16 patients from the center between January and August 2024 were collected as the Nomogram external validation set. The ROC and DCA were used to evaluate the performance of the model.
RESULTS: In the enhanced images, Model A built based on the enhanced 2-phase achieved the best average AUC, with a validation set of 0.764. Model B built based on the T2WI had better results, with a validation set of 0.693. Model C built by combining enhanced 2-phase and T2WI sequences had a mean AUC of 0.705 in the validation set. In addition, the tumor size, whether the tumor boundary was clear or not, and whether there was a coelom in the tumor tissue had a statistically significant effect on the LVI of IBC, and a clinical-radiomics nomogram was established. DCAs as well as Nomogram also indicate that Model A has good clinical utility. The AUC of the nomogram in the training set, internal validation set, and external validation set were 0.703, 0.615, and 0.609, respectively. The DCA also showed that the radiomics nomogram combined with clinical factors had good predictive ability for LVI.
CONCLUSION: In IBC, MRI radiomics can serve as a noninvasive predictor of LVI. The clinical-MRI radiomics model, as an efficient visual prognostic tool, shows promise in forecasting LVI. This highlights the significant potential of pre-radiomics prediction in enhancing treatment strategies.
Patients receive enzalutamide PO QD and rucaparib PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
<P>PROBLEM TO BE SOLVED: To provide a simple method for producing a super mineral material by which the super mineral components in a clean state without contamination are gathered from a natural world at a low cost entirely without hazard.  <P>SOLUTION: This method for producing the super mineral material comprises adding citric acid to a rock pulverized into a granular shape, or soaking the pulverized rock in the citric acid to elute the super mineral components. The rock pulverized into the granular shape preferably has a cube shape of about 3 mm size, and the rock pulverized into the granular shape is previously heated for several hours. Preferably, the heating is boiling with hot water. An original water of a hot spring having a strong acidity and an efficacy of a medicine is preferably added to the eluted super mineral components.  <P>COPYRIGHT: (C)2004,JPO
Transcatheter aortic valve implantation (TAVI) is now utilised as a less invasive alternative to surgical aortic valve replacement (SAVR) across the whole spectrum of surgical risk. Long-term durability of the bioprosthetic valves has become a key goal of TAVI as this procedure is now considered for younger and lower-risk populations. The purpose of this article is to present a state-of-the-art overview on the definition, aetiology, risk factors, mechanisms, diagnosis, clinical impact, and management of bioprosthetic valve dysfunction (BVD) and failure (BVF) following TAVI with a comparative perspective versus SAVR. Structural valve deterioration (SVD) is the main factor limiting the durability of the bioprosthetic valves used for TAVI or SAVR, but non-structural BVD, such as prosthesis-patient mismatch and paravalvular regurgitation, as well as valve thrombosis or endocarditis may also lead to BVF. The incidence of BVF related to SVD or other causes is low (<5%) at midterm (5- to 8-year) follow-up and compares favourably with that of SAVR. The long-term follow-up data of randomised trials conducted with the first generations of transcatheter heart valves also suggest similar valve durability in TAVI versus SAVR at 10 years, but these trials suffer from major survivorship bias, and the long-term durability of TAVI will need to be confirmed by the analysis of the low-risk TAVI versus SAVR trials at 10 years.
This is a Phase II, two parallel group study assessing the efficacy and safety of neoadjuvant and adjuvant targeted therapy in patients with stage IB-IIIA NSCLC harboring BRAF V600 or MET exon14 mutations. Eligible patients with BRAF V600 mutations will receive dabrafenib 150mg bid plus trametinib 2mg qd for 8 weeks before a surgical resection (neoadjuvant), and followed by up to 4 cycles of adjuvant chemotherapy, if receive adjuvant chemotherapy, up to four cycles, chemo regimen according to investigators' choice, and up to 2 years of adjuvant targeted therapy with dabrafenib plus trametinib. For patients with MET exon14 mutations, they will receive capmatinib 400mg bid for 8 weeks before surgery (neoadjuvant), followed by up to 4 cycles of adjuvant chemotherapy, about adjuvant chemotherapy same as BRAF V600 group, and up to 2 years of adjuvant targeted therapy with capmatinib post-surgery. During treatment, patients will visit their physicians regularly for disease and safety assessment. After the end of treatment, survival follow-up will be conducted every 3 months for up to 3 years. Approximately 40 evaluable patients will be enrolled in the study (20 patients in each cohort).
Plants have intricate mechanisms that tailor their defence responses to pathogens. WRKY transcription factors play a pivotal role in plant immunity by regulating various defence signalling pathways. Many WRKY genes are transcriptionally activated upon pathogen attack, but how their functions are regulated after transcription remains elusive. Here, we show that OsWRKY7 functions as a crucial positive regulator of rice basal immunity against Xanthomonas oryzae pv. oryzae (Xoo). The activity of OsWRKY7 was regulated at both translational and post-translational levels. Two translational products of OsWRKY7 were generated by alternative initiation. The full-length OsWRKY7 protein is normally degraded by the ubiquitin-proteasome system but was accumulated following elicitor or pathogen treatment, whereas the alternate product initiated from the downstream in-frame start codon was stable. Both the full and alternate OsWRKY7 proteins have transcriptional activities in yeast and rice cells, and overexpression of each form enhanced resistance to Xoo infection. Furthermore, disruption of the main AUG in rice increased the endogenous translation of the alternate stabilized form of OsWRKY7 and enhanced bacterial blight resistance. This study provides insights into the coordination of alternative translation and protein stability in the regulation of plant growth and basal defence mediated by the OsWRKY7 transcription factor, and also suggests a promising strategy to breed disease-resistant rice by translation initiation control.
The study drug will be given by intravenous infusion once weekly as long as the subject is deriving clinical benefit until disease progression or other treatment discontinuation criteria met, unacceptable toxicity, or subject's refusal, whichever occurs first. The dose-limiting toxicity observation period will be 28 days, reflecting adequate exposure for safety assessment. The dose-escalation scheme will follow a Bayesian logistic regression model. A safety review committee will monitor safety and recommend all cohort dosing decisions. The starting First In Human dose for AFM28 will be 25 mg i.v. and treatment in each cohort will utilize a staggered approach, with at least 7 days between the first dose of the first subject and the first dose of subsequent subjects. In order to gather additional Pharmacokinetics/ Pharmacodynamics and safety data to inform potential final dose escalation decisions and selection of one or more recommended phase 2 doses at selected dose levels, additional subjects may be enrolled in at least two cohorts consistent with backfilling a cohort (up to 12 subjects).
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to otorhinolaryngology. The method includes the study of nasal structures located in the frontal plane, such as the anastomosis of the sphenoid sinus. A rigid endoscope of 0 degrees is inserted into the nasal cavity. After that, a calibration tool is installed at the level of the contours of the anatomical holes, this function is performed by a surgical probe for an attic with a predetermined diameter of the working part. A video image of the installation of the above calibration tool is obtained. The photo fixation of the received image is stored on the computing device. In the saved image, using a computer program for image analysis and processing, using the function for delineating uneven edges, the circumference of the working part of the calibration tool and the contour of the resulting nose hole are alternately selected. The quantitative values of the selected circumference of the working part of the calibration tool and the contour of the nose hole are determined, followed by the determination of the hole area in absolute units, cm2, using the program. In addition to the holes at the mouth of the sphenoid sinus, the condition of the nasal valve openings is also examined, while the calibration tool is installed at the level of the landmarks of the internal nasal valve. A mobile phone is used as a computing device. At the same time, the NoseApp program for the mobile phone is used, and the automatic calculation is made on the basis of the Canny edge detector. After that, a database is formed for each patient with further comparison and dynamic observation of the previous processed photos.EFFECT: method makes it possible to increase the efficiency of assessing the condition of intra-nasal anatomical holes due to the accuracy, ergonomics of determining the area of these holes in the surgical treatment of rhinologic patients.1 cl, 6 dwg, 2 ex
Hepatitis B virus (HBV) is a small deoxyribonucleic acid (DNA) virus that infects the liver and can cause either acute or chronic infection. It consists of a so-called nucleocapsid in which viral DNA is packed with hepatitis B core protein (HBc) and membranous envelope containing hepatitis B surface antigen (HBsAg). Chronic HBV infection may lead to serious illnesses like cirrhosis and hepatocellular carcinoma (HCC). Oral treatment with NAs is effective at suppressing viral DNA formation and lowering virus concentration in blood to levels below lower limit of quantification (LLOQ). JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection designed to treat chronic HBV infection via ribonucleic acid interference mechanism but rarely lead to functional cure defined as sustained loss of HBs Ag and HBV DNA in serum. JNJ-56136379 is an orally administered capsid assembly modulator that is being developed for treatment of chronic HBV infection. The aim of study is to evaluate efficacy of 48-week study intervention with JNJ-3989+JNJ-6379+NA regimen compared to NA alone, assessed by HBsAg seroclearance at Week 72 (i.e., 24 weeks after completion of all study interventions at Week 48) without restarting NA treatment in HBeAg negative virologically suppressed chronic hepatitis B (CHB) infected participants who received NA treatment for at least 2 years prior to screening. The study will be 2.3 years and will be conducted in 3 phases: a screening phase (4 weeks), a study intervention phase (48 weeks), and a follow-up phase (48 weeks). Safety will be evaluated by AEs including AEs of special interest to any of the study interventions, clinical laboratory tests, ECGs, vital signs, and physical examinations.
Bipolar Disorder (BD) is a common, severe, chronic and often life-threatening illness. Suicide is the cause of death in 10-20% of individuals with BD. The discovery of lithium's efficacy as a mood-stabilizing agent has since revolutionized the treatment of patients with BD. However, approximately 50% of patients do not respond fully to lithium, and the biochemical basis for lithium's antimanic and mood-stabilizing actions remains to be fully elucidated. Elucidation of the mechanism(s) by which lithium stabilizes an underlying dysregulation of limbic and limbic-associated function also offers the potential to delineate the underlying pathophysiology of BD; however, a major problem inherent in neuropharmacologic research is the difficulty in attributing therapeutic relevance to any observed biochemical finding. One powerful approach is to identify common biochemical targets, which are modified by drugs belonging to the same therapeutic class (e.g. mood-stabilizing agents) but possessing distinct chemical structures when administered in a therapeutically relevant paradigm (i.e., effects which are observed upon chronic drug administration, and yet persist beyond abrupt drug discontinuation). In this context, it is noteworthy that both valproic acid (VPA) and lithium, with different chemical structures, belong to the same therapeutic class and cause considerable inhibition of protein kinase C (PKC). The PKC signaling pathway is clearly a target for the actions of two structurally highly dissimilar antimanic agents -- lithium and VPA. Do these effects of lithium and VPA on PKC signaling have any clinical relevance? There is thus a clear need to investigate the potential efficacy of a direct PKC inhibitor in the treatment of acute mania. There is currently only one relatively selective PKC inhibitor available for human use- Tamoxifen. Tamoxifen (TAM), a synthetic nonsteroidal antiestrogen, has been widely used in the treatment of breast cancer. TAM's potent inhibitory effects on PKC are striking. Recently, our group conducted the first open-label study with TAM in acute mania. In this study, TAM resulted in a significant decrease in manic symptoms within a short period of time (3-7 days).

The overarching goal of this proposal is to test the hypothesis that PKC inhibition is part of the mechanism of the therapeutic effect of mood stabilizing drugs. The proposal derives from and builds on our published open-label study of TAM in acute mania (Bebchuk et al., 2000). However, the efficacy of TAM monotherapy in acute mania has only been reported in an open-label study and has not yet been evaluated in a randomized, double blind, placebo-controlled study.

Male or female patients, ages 18 to 65, with a diagnosis of bipolar I disorder manic or mixed (with or without psychotic features), will be randomized to double-blind treatment to receive either TAM (20-140 mg/day) or placebo, for a period of 3 weeks. Following this acute period, the patients will receive either open-label TAM or treatment as clinically indicated. Approximately 50 patients with acute mania will be enrolled in the study. Biochemical measures will be obtained during the study.
PURPOSE:A cosmetic useful as a skin cosmetic such as nutritive cream, hand cream, milky lotion, toilet lotion, etc. or a scalp cosmetic, effective for treating chaps, cracks in the skin, or scalp, improving chapped skin, containing a mucopolysaccharide and a brown dyestuff of an extract of crude sugar. CONSTITUTION:A cosmetic containing both a mucopolysaccharide and a substantially pure brown dyestuff extracted from crude sugar. Hyaluronic acid, chondroitin 4-sulfate, and chondroitin 6-sulfate may be preferably cited as the mucopolysaccharide and its amount added is 0.001-5.0wt% preferably 0.05- 3.0wt% based on the total amount of cosmetic. The brown dyestuff extracted from crude sugar, for example, is obtained by dissolving crude sugar in water, treating the solution with an adsorbent, washing the adsorbent with water to remove a sugar component, so that only sugar dyestuff is adsorbed on it. The sugar dyestuff is released by the use of an alcohol, and the eluate is evaporated to dryness under reduced pressure. An amount of the dyestuff added is preferably 0.001-1.0wt%.
Managing obese patients on the ventilator can be difficult due to the changes in their respiratory mechanics with little evidence as to best practices. This research will assess the utility of transpulmonary pressures in guiding mechanical ventilation in obese patients. This study with specifically look at whether using transpulmonary pressure guided positive end expiratory pressure (PEEP) titration for ventilation and spontaneous breathing trials (SBT) will shorten the time to liberation for obese patients on invasive mechanical ventilation for respiratory failure. The transpulmonary pressures will be calculated daily for all patients. Patients will also be assessed daily for readiness for SBT. In the intervention group, subjects' PEEP will be titrated to achieve an end expiratory transpulmonary pressure of 0-2 cm H2O. This PEEP will be used for the SBT and clinicians will be encouraged to keep their patients on this PEEP after the SBT if they are not extubated. In the control group, patients will also be assessed daily for SBT readiness but will be managed with standard set pressures of 5 to 10 cm H2O of PEEP and 5 to 8 cm H2O of pressure above PEEP. The primary team can perform a T piece trial prior to extubation as clinically indicated.
An aspect of the present disclosure is related to a medication dispensing device that includes a housing with an interior. A plurality of cartridge slots are located in the interior, and each of the cartridge slots includes a drive mechanism. A plurality of cartridges are removably disposed in respective ones of the cartridge slots. Each cartridge includes a stationary hub and a rotational wheel. The stationary hub has a window, and the rotational wheel has a plurality of medication chambers that contain medications. The rotational wheel is disposed in the stationary hub. The drive mechanism of the respective cartridge slot is operably connected with the drive wheel and is configured to rotate the rotational wheel relative to the stationary hub to selectively align the medication chambers with the window to dispense the medications contained in the medication chambers out of the cartridge.